IGF Level in Breast Cancer Patients Treated With Metformin

Metformin Effect as a Chemotherapeutic Adjuvant on Level of IGF in Non-diabetic Breast Cancer Patients

The purpose of this study is to examine the impact of metformin as an adjuvant to chemotherapy on IGF levels in both progressing and non progressing cases of metastatic breast cancer in female patients.

One hundred and seven women with metastatic breast cancer (MBC) are randomly assigned to either a metformin (500 mg twice daily) or placebo (placebo) group during chemotherapy. All patients followed the standard chemotherapy protocol developed by the South Egypt Cancer Institute (SECI). Blood IGF-1 levels were measured at the start of treatment (baseline) and again six months later.

Inclusion Criteria:

• Female patients with MBC
• patients older than 18
• nondiabetic patients
• patients who received only chemotherapy

Exclusion Criteria:

• patients with non-metastatic breast cancer
• patients receiving hormonal therapy or radiotherapy
• patients with diabetes
• history of cardiac diseases
• hypersensitivity, or allergy to metformin.